Literature DB >> 19773716

Adult ADHD and comorbid depressive disorders: diagnostic challenges and treatment options.

David Goodman1.   

Abstract

Attention-deficit/hyperactivity disorder (ADHD) and major depressive disorder (MDD) are separately common mental health conditions that can have an adverse effect on a patient's quality of life if left untreated. These disorders frequently co-occur with one another, which can lead to increased patient suffering and diagnostic challenges for the treating clinician. In the United States adult population, epidemiological data show that the prevalence rate for MDD is 6.7%, while the ADHD prevalence rate in US adults is 4.4%. This epidemiological data represents the general population and likely underestimates the prevalence rates in clinic or practice patients. Examining the concurrent comorbid rate, if a patient has MDD, the likelihood of that patient also having ADHD is 18.6%; if the patient has ADHD, the likelihood of that patient having comorbid MDD is 9.4%. If the patient has dysthymia, the comorbid rate of ADHD is 12.8%, while those adults with ADHD have a comorbid rate of dysthymia of 22.6%.

Entities:  

Mesh:

Year:  2009        PMID: 19773716     DOI: 10.1017/s1092852900024810

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  3 in total

1.  [Military service with adult attention deficit hyperactivity disorder: adaptability of affected soldiers on active service in the German Armed Forces].

Authors:  P Zimmermann; M Jenuwein; K H Biesold; A Heinz; A Ströhle
Journal:  Nervenarzt       Date:  2011-03       Impact factor: 1.214

2.  Combining Stimulants and Monoamine Oxidase Inhibitors: A Reexamination of the Literature and a Report of a New Treatment Combination.

Authors:  Joshua A Israel
Journal:  Prim Care Companion CNS Disord       Date:  2015-12-10

Review 3.  Clinical Presentation, Diagnosis and Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Older Adults: A Review of the Evidence and its Implications for Clinical Care.

Authors:  David W Goodman; Sara Mitchell; Lauren Rhodewalt; Craig B H Surman
Journal:  Drugs Aging       Date:  2016-01       Impact factor: 3.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.